Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Rhythm Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company specializes in the development of molecule therapies targeting metabolic pathways for the treatment of obesity, diabetes, and gastrointestinal functional disorders. Rhythm Pharmaceuticals serves patients in the United States.
Website: rhythmtx.com



Growth: Good revenue growth rate 54.5%, there is slowdown compared to average historical growth rates 120.3%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is negative, -100.0%. On average the margin is improving steadily. Gross margin is high, +89.3%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 554.0% higher than minimum and 12.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.9x by EV / Sales multiple , the company can be 95.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $1.1 mln (-0.015% of cap.)

Key Financials (Download financials)

Ticker: RYTM
Share price, USD:  (0.0%)103.39
year average price 83.91  


year start price 59.18 2025-02-08

min close price 46.95 2025-04-04

max close price 117.52 2025-12-11

current price 103.39 2026-02-07
Common stocks: 66 261 055

Dividend Yield:  0.0%
EV / Sales: 39.4x
Margin (EBITDA LTM / Revenue): -100.0%
Fundamental value created in LTM:
Market Cap ($m): 6 851
Net Debt ($m): 242
EV (Enterprise Value): 7 093
Price to Book: 46.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-08fool.com

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

2025-11-04seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript

2025-10-28zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

2025-09-24seekingalpha.com

Rhythm Pharmaceuticals, Inc. - Special Call

2025-09-21fool.com

2 Under-the-Radar Stocks That Could Soar

2025-09-09seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-08-05seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

2025-07-10zacks.com

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

2025-07-10globenewswire.com

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

2025-07-09globenewswire.com

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-04 2025-08-05 2024-11-06 2024-08-14 2024-05-07 2023-11-08 2023-08-01 2023-05-02 2022-11-08
acceptedDate 2025-11-04 16:06:44 2025-08-05 16:19:04 2025-02-28 08:19:11 2024-11-06 08:20:29 2024-08-14 16:06:56 2024-05-07 16:43:31 2024-02-29 16:05:53 2023-11-08 16:30:38 2023-08-01 16:27:09 2023-05-02 16:30:47 2023-03-01 17:27:17 2022-11-08 14:06:50 2022-03-01 15:53:06 2021-03-01 12:33:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 51M 49M 130M 33M 29M 26M 77M 23M 19M 11M 24M 4M 3M 0
costOfRevenue 5M 6M 13M 4M 3M 3M 9M 2M 2M 1M 2M 497 000 599 000 690 000
grossProfit 46M 43M 117M 29M 26M 23M 68M 20M 17M 10M 22M 4M 3M -690 000
grossProfitRatio 0.893 0.886 0.885 0.893 0.885 0.893 0.884 0.876 0.884
researchAndDevelopmentExpenses 46M 42M 238M 38M 30M 128M 135M 34M 34M 38M 109M 21M 104M 90M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 52M 46M 144M 35M 36M 34M 118M 30M 30M 25M 92M 22M 68M 46M
otherExpenses 0 0 0 0 302 000 524 000 0 -159 000 -17 000 -27 000 0 0 0 -690 000
operatingExpenses 98M 88M 382M 73M 66M 163M 252M 64M 64M 63M 201M 43M 173M 136M
costAndExpenses 104M 94M 396M 77M 70M 166M 262M 66M 66M 64M 203M 44M 173M 137M
interestIncome 4M 3M 15M 4M 4M 3M 14M 3M 3M 3M 4M 920 000 447 000 3M
interestExpense 5M 6M 21M 5M 5M 5M 14M 3M 3M 3M 5M 2M 0 0
depreciationAndAmortization 304 000 379 000 2M 385 000 391 000 405 000 2M 3M 3M 3M 2M 992 000 1M 690 000
ebitda -48M -40M -238M -38M -27M -139M -168M -41M -43M -49M -174M -38M -68M -136M
ebitdaratio -0.931 -0.827 -1.154 -1.379 -5.372 -1.806 -2.258 -4.283 -8.934
operatingIncome -53M -45M -266M -44M -40M -140M -184M -44M -47M -53M -179M -39M -170M -137M
operatingIncomeRatio -1.026 -0.934 -1.32 -1.392 -5.387 -1.953 -2.425 -4.58 -9.166
totalOtherIncomeExpensesNet -140 000 -999 000 5M -100 000 9M -1M 243 000 -159 000 -17 000 352 000 -2M -2M 100M 3M
incomeBeforeTax -53M -46M -260M -44M -32M -141M -184M -44M -47M -52M -181M -41M -70M -134M
incomeBeforeTaxRatio -1.029 -0.954 -1.323 -1.093 -5.433 -1.946 -2.43 -4.55 -9.538
incomeTaxExpense 111 000 337 000 346 000 -344 000 479 000 300 000 564 000 368 000 82 000 -352 000 0 2M 0 0
netIncome -53M -47M -261M -45M -32M -141M -185M -44M -47M -52M -181M -42M -70M -131M
netIncomeRatio -1.031 -0.961 -1.352 -1.109 -5.444 -1.962 -2.43 -4.519 -9.91
eps -0.82 -0.75 -4.34 -0.71 -0.53 -2.35 -3.2 -0.76 -0.82 -0.91 -3.51 -0.83 -1.37 -2.96
epsdiluted -0.82 -0.75 -0.71 -0.53 -2.35 -0.76 -0.82 -0.91 -0.83
weightedAverageShsOut 64M 64M 61M 61M 61M 60M 58M 58M 57M 57M 52M 51M 50M 44M
weightedAverageShsOutDil 64M 64M 61M 61M 61M 60M 58M 58M 57M 57M 52M 51M 50M 44M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -6M 53 000 -1M 447 000 3M
ebit -240M -170M -176M -70M -137M
nonOperatingIncomeExcludingInterest -26M -14M -3M -100M 0
netIncomeFromContinuingOperations -261M -185M -181M -70M -134M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 3M
netIncomeDeductions 0 0 0 0 3M
bottomLineNetIncome -265M -185M -181M -70M -134M
epsDiluted -4.34 -3.2 -3.51 -1.37 -2.96

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-04 2025-08-05 2024-11-06 2024-08-14 2024-05-07 2023-11-08 2023-08-01 2023-05-02 2022-11-08
acceptedDate 2025-11-04 16:06:44 2025-08-05 16:19:04 2025-02-28 08:19:11 2024-11-06 08:20:29 2024-08-14 16:06:56 2024-05-07 16:43:31 2024-02-29 16:05:53 2023-11-08 16:30:38 2023-08-01 16:27:09 2023-05-02 16:30:47 2023-03-01 17:27:17 2022-11-08 14:06:50 2022-03-01 15:53:06 2021-03-01 12:33:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 52M 136M 89M 48M 162M 53M 60M 65M 116M 110M 128M 185M 59M 101M
shortTermInvestments 364M 155M 231M 251M 157M 148M 216M 235M 138M 185M 206M 163M 236M 72M
cashAndShortTermInvestments 416M 291M 321M 298M 319M 201M 276M 299M 254M 295M 333M 348M 295M 173M
netReceivables 33M 26M 19M 19M 18M 15M 15M 15M 14M 8M 6M 3M 1M 0
inventory 0 19M 19M 14M 12M 9M 9M 8M 6M 5M 3M 0 111 000 0
otherCurrentAssets 46M 25M 9M 9M 9M 11M 7M 8M 10M 10M 7M 11M 4M 3M
totalCurrentAssets 495M 361M 374M 340M 357M 236M 308M 329M 284M 318M 354M 362M 308M 182M
propertyPlantEquipmentNet 0 4M 4M 4M 5M 2M 2M 2M 3M 3M 3M 4M 4M 5M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 6M 6M 6M 6M 7M 7M 7M 7M 7M 8M 8M 0 5M 0
goodwillAndIntangibleAssets 6M 6M 6M 6M 7M 7M 7M 7M 7M 8M 8M 8M 5M 0
longTermInvestments 671 000 0 0 462 000 460 000 460 000 0 328 000 328 000 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 -328 000 -328 000 0 0 0 0 0
otherNonCurrentAssets 6M 3M 8M 12M 13M 14M 15M 15M 16M 17M 17M 16M 12M 403 000
totalNonCurrentAssets 12M 12M 18M 23M 24M 23M 24M 25M 26M 28M 28M 28M 21M 5M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 507M 373M 392M 364M 382M 259M 333M 354M 310M 346M 382M 390M 330M 187M
accountPayables 14M 16M 12M 5M 5M 8M 5M 4M 8M 13M 5M 5M 6M 5M
shortTermDebt 624 000 4M 0 0 2M 793 000 0 748 000 726 000 705 000 0 664 000 0 0
taxPayables -53M 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 1M 1M 1M 1M 1M 1M 1M 1M 1M 2M 7M 0
otherCurrentLiabilities 143M 109M 44M 91M 47M 45M 5M 44M 36M 31M 2M 26M 800 000 180 000
totalCurrentLiabilities 104M 129M 116M 98M 55M 54M 55M 50M 46M 46M 40M 33M 43M 18M
longTermDebt 150M 255M 0 8M 112M 107M 0 692 000 888 000 1M 0 1M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 103M 0 108M 247M 36M 36M 107M 106M 81M 79M 77M 68M 0 0
totalNonCurrentLiabilities 254M 255M 112M 255M 288M 143M 108M 107M 82M 80M 78M 75M 2M 3M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 4M 4M 4M 4M 4M 284 000 1M 1M 2M 2M 2M 2M 3M 3M
totalLiabilities 358M 385M 228M 352M 343M 197M 163M 157M 128M 126M 118M 108M 45M 21M
preferredStock 0 0 143M 0 140M 0 0 0 0 0 0 0 0 0
commonStock 67 000 64 000 61 000 61 000 60 000 60 000 59 000 59 000 57 000 56 000 56 000 56 000 50 000 44 000
retainedEarnings -1 304M -1 251M -1 155M -1 112M -1 068M -1 036M -895M -853M -809M -762M -710M -668M -529M -459M
accumulatedOtherComprehensiveIncomeLoss -926 000 -2M -39 000 -604 000 -617 000 -181 000 134 000 -113 000 -14 000 -6000 -92 000 -339 000 -1000 49 000
othertotalStockholdersEquity 1 454M 1 242M 1 124M 828M 1 098M 1 051M 991M 982M 949M
totalStockholdersEquity 149M -12M 165M 11M 39M 62M 170M 197M 182M 220M 264M 281M 284M 167M
totalEquity 149M -12M 165M 11M 39M 62M 170M 197M 182M 220M 264M 281M 284M 167M
totalLiabilitiesAndStockholdersEquity 507M 373M 364M 382M 259M 354M 310M 346M 390M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 507M 373M 392M 364M 382M 259M 333M 354M 310M 346M 382M 390M 330M 187M
totalInvestments 365M 155M 231M 251M 158M 148M 216M 235M 138M 185M 206M 163M 236M 72M
totalDebt 151M 259M 4M 4M 253M 108M 1M 1M 2M 2M 2M 2M 3M 3M
netDebt 99M 124M -85M -43M 91M 55M -59M -63M -114M -108M -126M -183M -57M -98M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 19M 15M 6M 1M 0
otherReceivables 0 0 0 0 0
prepaids 8M 2M 4M 8M 6M
totalPayables 12M 5M 5M 6M 5M
otherPayables 0 0 0 0 0
accruedExpenses 58M 43M 30M 29M 12M
capitalLeaseObligationsCurrent 0 770 000 684 000 606 000 535 000
capitalLeaseObligationsNonCurrent 4M 490 000 1M 2M 3M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 177M 1 064M 974M 813M 626M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM RYTM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-04 2025-08-05 2024-11-06 2024-08-14 2024-05-07 2023-11-08 2023-08-01 2023-05-02 2022-11-08
acceptedDate 2025-11-04 16:06:44 2025-08-05 16:19:04 2025-02-28 08:19:11 2024-11-06 08:20:29 2024-08-14 16:06:56 2024-05-07 16:43:31 2024-02-29 16:05:53 2023-11-08 16:30:38 2023-08-01 16:27:09 2023-05-02 16:30:47 2023-03-01 17:27:17 2022-11-08 14:06:50 2022-03-01 15:53:06 2021-03-01 12:33:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -53M -47M -261M -44M -32M -141M -185M -44M -47M -52M -181M -41M -70M -134M
depreciationAndAmortization 304 000 379 000 2M 384 000 391 000 405 000 2M 442 000 442 000 457 000 2M 442 000 1M 690 000
deferredIncomeTax 0 0 0 0 0 0 0 -235 000 135 000 0 0 0 -100M 0
stockBasedCompensation 19M 16M 40M 11M 10M 8M 33M 9M 9M 6M 20M 5M 21M 17M
changeInWorkingCapital 3M 5M 11M 4M -2M -2M 5M 3M -7M 413 000 -20M -14M 2M -6M
accountsReceivables -7M -8M -4M -2M -3M 172 000 -9M -710 000 -6M -2M -5M 0 -1M 0
inventory -2M 479 000 -10M -2M -3M 117 000 -6M -2M -690 000 -3M -3M 0 -11 000 0
accountsPayables 11M 13M 22M 8M 482 000 -1M 15M 4M 661 000 5M 2M -13M 18M -6M
otherWorkingCapital 1M -1M 2M 435 000 4M -1M 4M 1M -2M -291 000 -13M -2M -15M 551 000
otherNonCashItems 4M 3M 95M 3M 12M 104M 9M 3M 3M 9M 6M 3M -250 000 -234 000
netCashProvidedByOperatingActivities -27M -23M -114M -25M -29M -41M -136M -29M -41M -36M -173M -47M -146M -122M
investmentsInPropertyPlantAndEquipment 0 0 0 -500 000 0 -40M -47 000 -1000 -875 000 -47 000 -4M -95 000 -5M -214 000
acquisitionsNet 0 0 0 0 0 0 0 0 875 000 0 4M 0 100M 0
purchasesOfInvestments -268M -27M -268M -136M -66M 0 -355M -169M -75M -70M -252M -101M -525M -87M
salesMaturitiesOfInvestments 62M 81M 261M 45M 58M 70M 355M 75M 125M 93M 284M 61M 361M 246M
otherInvestingActivites -40M 0 0 -9M -40M -272 000 -875 000 -5M 0
netCashUsedForInvestingActivites -246M 54M -91M -9M 30M -95M 48M 18M -40M
debtRepayment 0 0 0 0 -3M -2M -1M 0 0
commonStockIssued 189M 0 6M 140M 7M 51M 341 000 553 000 117M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 645 000 -889 000 2M 146M -3M 24M 0 -686 000 42M
netCashUsedProvidedByFinancingActivities 189M -889 000 2M 146M 4M 73M -965 000 -133 000 159M
effectOfForexChangesOnCash 304 000 -279 000 2000 -603 000 -301 000 -71 000 -142 000 77 000 -113 000 86 000 0 0 0 0
netChangeInCash -83M 30M 29M -114M 108M -7M -68M -51M 6M -18M 68M 72M -42M 39M
cashAtEndOfPeriod 53M 136M 90M 48M 162M 53M 60M 65M 116M 110M 128M 185M 60M 101M
cashAtBeginningOfPeriod 136M 107M 60M 162M 53M 60M 128M 116M 110M 128M 60M 114M 101M 63M
operatingCashFlow -27M -23M -114M -25M -29M -41M -136M -29M -41M -36M -173M -47M -146M -122M
capitalExpenditure 0 0 0 40M 0 -40M -47 000 -1000 -875 000 -47 000 -4M -95 000 -5M -214 000
freeCashFlow -27M -23M -114M 15M -29M -81M -136M -29M -42M -36M -178M -47M -151M -122M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-03-01 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -41M -6M -4M 7M 0
netCashProvidedByInvestingActivities -48M -6M 28M -62M 159M
netDebtIssuance -13M 0 0 0 0
longTermNetDebtIssuance -13M 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 195M 49M 131M 162M 0
netCommonStockIssuance 195M 49M 131M 162M 0
commonStockIssuance 195M 49M 131M 162M 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -4M 0 0 0 0
commonDividendsPaid -4M 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 13M 25M 83M 5M 2M
netCashProvidedByFinancingActivities 191M 74M 214M 166M 2M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-11-05 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-03-07 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-04 21:06 ET
Rhythm Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-04 12:05 ET
Rhythm Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-04 12:05 ET
Rhythm Pharmaceuticals published news for 2025 q3
SEC form 10
2025-08-05 20:19 ET
Rhythm Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-05 11:05 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-05 11:05 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-11 11:00 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-11 11:00 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-11 11:00 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-09 20:39 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-09 20:39 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-09 20:39 ET
Rhythm Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-07 20:46 ET
Rhythm Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-07 11:01 ET
Rhythm Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-07 11:01 ET
Rhythm Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Rhythm Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-07 11:01 ET
Rhythm Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-07 11:01 ET
Rhythm Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-07 11:01 ET
Rhythm Pharmaceuticals published news for 2025 q1
SEC form 8
2025-03-20 20:05 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 8
2025-03-20 20:05 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-28 13:19 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Rhythm Pharmaceuticals reported for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Rhythm Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-06 08:20 ET
Rhythm Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-05 16:02 ET
Rhythm Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-05 16:02 ET
Rhythm Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-06 16:21 ET
Rhythm Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 07:00 ET
Rhythm Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 07:00 ET
Rhythm Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Rhythm Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 16:43 ET
Rhythm Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 07:10 ET
Rhythm Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 07:10 ET
Rhythm Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Rhythm Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Rhythm Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-22 07:01 ET
Rhythm Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-22 07:01 ET
Rhythm Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-08 16:30 ET
Rhythm Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Rhythm Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-07 07:05 ET
Rhythm Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-01 16:27 ET
Rhythm Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-01 07:05 ET
Rhythm Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Rhythm Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Rhythm Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-22 16:47 ET
Rhythm Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Rhythm Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Rhythm Pharmaceuticals reported for 2023 q1
SEC form 6
2023-04-27 17:08 ET
Rhythm Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-10 14:46 ET
Rhythm Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-01 17:27 ET
Rhythm Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-01 07:05 ET
Rhythm Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 16:06 ET
Rhythm Pharmaceuticals published news for 2022 q4
SEC form 10
2022-11-08 14:06 ET
Rhythm Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-08 07:03 ET
Rhythm Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 16:55 ET
Rhythm Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-15 16:02 ET
Rhythm Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-03 16:18 ET
Rhythm Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-02 07:02 ET
Rhythm Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-16 17:11 ET
Rhythm Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-10 16:30 ET
Rhythm Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-03 15:27 ET
Rhythm Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-03 07:05 ET
Rhythm Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Rhythm Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-28 16:40 ET
Rhythm Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-06 08:01 ET
Rhythm Pharmaceuticals published news for 2022 q1
SEC form 10
2022-03-01 15:53 ET
Rhythm Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 15:06 ET
Rhythm Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-11 21:30 ET
Rhythm Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-08 17:08 ET
Rhythm Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-02 14:13 ET
Rhythm Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-02 07:05 ET
Rhythm Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-15 18:49 ET
Rhythm Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-02 16:15 ET
Rhythm Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 15:41 ET
Rhythm Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-03 07:05 ET
Rhythm Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-27 20:09 ET
Rhythm Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-14 16:04 ET
Rhythm Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-03 08:54 ET
Rhythm Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-03 08:36 ET
Rhythm Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-03 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-03 00:00 ET
Rhythm Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-27 16:06 ET
Rhythm Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:45 ET
Rhythm Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-30 16:47 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-16 16:02 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 10
2021-03-01 12:33 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-01 09:01 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-05 17:27 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 16:42 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-02 20:09 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-05 16:49 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-04 16:32 ET
Rhythm Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-11 16:10 ET
Rhythm Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-11 16:10 ET
Rhythm Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-11 16:01 ET
Rhythm Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-10 16:05 ET
Rhythm Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-02 11:35 ET
Rhythm Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-02 09:32 ET
Rhythm Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-06 16:05 ET
Rhythm Pharmaceuticals published news for 2020 q3